At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Zinc Sulfate 220 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting
In Brief
A Phase 4 clinical trial evaluating Zinc Sulfate 220 MG and Placebo for Corona Virus Infection. Completed, enrolled 3 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorona Virus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedNov 9, 2020
Enrollment StartDec 20, 2020
Primary CompletionFeb 8, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.6 years ago
Interventions
Zinc Sulfate 220 MGdietary
220mg once daily for 5 days
Placebodrug
Once daily for 5 days